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Abstract: Milk powder and gluten are common components in Swedish infants’ diets. Whereas
large intakes of gluten early in life increases the risk of celiac disease in genetically at-risk Swedish
children, no study has yet evaluated if intake of milk powder by 2 years of age is associated with celiac
disease. A 1-to-3 nested case-control study, comprised of 207 celiac disease children and 621 controls
matched for sex, birth year, and HLA genotype, was performed on a birth cohort of HLA-DR3-DQ2
and/or DR4-DQ8-positive children. Subjects were screened annually for celiac disease using tissue
transglutaminase autoantibodies (tTGA). Three-day food records estimated the mean intake of milk
powder at ages 6 months, 9 months, 12 months, 18 months, and 24 months. Conditional logistic
regression calculated odds ratios (OR) at last intake prior to seroconversion of tTGA positivity, and
for each time-point respectively and adjusted for having a first-degree relative with celiac disease and
gluten intake. Intake of milk powder prior to seroconversion of tTGA positivity was not associated
with celiac disease (OR = 1.00; 95% CI = 0.99, 1.03; p = 0.763). In conclusion, intake of milk powder in
early childhood is not associated with celiac disease in genetically susceptible children.
Keywords: infant feeding; Sweden; HLA; milk powder; formula; gluten; commercial infant foods
1. Introduction
Celiac disease is a common chronic small bowel disease caused by intolerance to gluten found
in foods containing wheat, rye or barley [1]. It has been debated whether the global differences in
prevalence are due to variations in infant feeding practices [2]. One affecting factor could be variations
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in gluten intake during the first years of life [3]. The effects of dairy product intake on the risk of celiac
disease is less studied. Although the vast majority of patients with celiac disease have antibodies
directed against tissue transglutaminase (tTGA) [4], a proportion also have detectable antibodies
against milk protein [5]. Although a recent study did not find avoidance of cow´s milk-based products
to protect from celiac disease compared with extensively hydrolyzed formula [5], it is not entirely clear
whether other components in milk products may trigger celiac disease.
Commercial instant porridges and cereal milk drinks based on milk powder and gluten containing
cereals are common infant food products in some parts of the world [6]. In milk powder production,
advanced glycation end products (AGEs) are formed through Maillard reactions [7]. AGEs have
pro-inflammatory effects and may induce increased oxidative stress in adults [8]. Notably, levels
of AGEs increase during storage of commercial instant porridge and cereal milk drinks in room
temperatures [9]. It could therefore be hypothesized that a high intake of commercial instant porridge
and cereal milk drinks containing high concentrations of AGEs cause an initial inflammation that
results in an increased gut permeability to gluten antigens that eventually leads to celiac disease in
genetic at risk individuals.
The aim of this study was to investigate if intake of milk powder is associated with celiac disease in
children. We prospectively collected food data from a birth cohort of genetically predisposed children
that later developed celiac disease and compared it to matched controls in a nested case-control study.
2. Subjects and Methods
2.1. Study Population
The Environmental Determinants of Diabetes in the Young (TEDDY) study is an observational
study conducted at 6 clinical centers in Finland, Germany, Sweden and the United States, investigating
the environmental factors associated with type 1 diabetes and celiac disease [10]. Children carrying
any of the HLA genotypes associated with type 1 diabetes and celiac disease were invited to participate
in a 15-year follow-up [10], and among the enrolled participants 2525 were from the Swedish site.
The TEDDY study is monitored by the National Institutes of Health and has been approved by ethics
review boards at individual sites and informed consent from a parent or primary caretaker were
obtained prior to screening.
2.2. Screening for Celiac Disease
Annual screening for celiac disease begins at 2 years of age by measurement of IgA and IgG
autoantibodies against tTGA using radioligand binding assays as previously described [1]. Children
positive for tTGA have their blood samples analyzed to determine the closest time point of tTGA
seroconversion. Children positive for tTGA in two consecutive samples were evaluated for celiac
disease at their health care provider. Diagnosis of celiac disease was established if a child had a biopsy
showing Marsh score of 2 or higher and responded to a gluten-free diet with a significant decrease in
tTGA levels.
As of July 31 in 2016, 2,077 Swedish TEDDY children had been screened for tTGA of whom 504
(24%) were tTGA positive at median 30 months of age (first quartile (Q1): 21, third quartile (Q3): 53)
and 85 of those (17%) children seroconverted to tTGA prior to or at 24 months of age. Among the 238
tTGA positive children that were finally investigated with an intestinal biopsy, 207 of the 2077 (10%)
children were diagnosed with celiac disease at median 45 months of age (Q1: 33, Q3: 70) (Figure 1).
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Figure 1. Flowchart of the study population.
2.3. Study Design
A nested case-control design included the 207 cases with biopsy-proven celiac disease and
3 controls randomly selected from the cohort for each case after matching on gender, the number of
HLA DQ2 alleles and birth year (i.e., 1–3 nested case-control design) (Table 1). All controls were free of
biopsy-proven celiac disease within 3 months of the matched case’s age of biopsy, as well as tTGA
negative within 3 months of the matched case’s age of seroconversion. In this nested case-control
study, 39 cases were selected as controls until seroconversion of tTGA.
Table 1. Characteristics of the identified cases with celiac disease in the Swedish TEDDY birth cohort
used as matching f ctors in a ested 1-3 case-control study.
Matching Variable Cases N = 207 (%)
Sex
- Female 131 (63.3)
- Male 76 (36.7)
Birth year
- 2004 11 (5.3)
- 2005 39 (18.8)
- 2006 28 (13.5)
- 2007 41 (19.8)
- 2008 37 (17.9)
- 2009 46 (22.2)
- 2010 5 (2.4)
HLA-genotype
- DQ2/DQ8 64 (30.9)
- DQ8/DQ8 35 (16.9)
- DQ2/DQ2 100 (48.3)
- Other 8 (3.9)
Nutrients 2018, 10, 550 4 of 9
2.4. Dietary Assessment
A study nurse collected a 24-h dietary recall at the first visit between 3 and 4.5 months of
age. Three-day food records, including two weekdays and one weekend day, were then collected at
follow-up visits at 6 months, 9 months, 12 months, 18 months, and 24 months of age, respectively.
Normal food habits were encouraged during the time of the food record collection. Parents were
provided with a manual including written instructions, as well as photos of portion sizes and drawings
of foods of different sizes and as reference. When the child started daycare, a set of separate food
record sheets and manual were provided for the daycare personnel. At the study visits, the study nurse
performed a face-to-face interview, probing for missing or unclear information and revising the food
record accordingly. A trained study dietitian or nutritionist entered the dietary information in a food
database. The TEDDY database for Sweden was based on the Swedish National Food Composition
Database, with information about nutrient content for foods and standard recipes for several composite
dishes [11]. Products and brands different from standard food items in ingredients or nutritional values
as well as unique recipes recorded by families were added to the database. For commercial baby foods,
recipes were created based on the ingredient list together with information on the nutritional value, and
added as a new food item if it changed in nutritional value or content. The study personnel entering
the food data reached consensus estimates for the weight of foods when there was no information in
the national food database or from the producer.
Intake of milk powder was either obtained directly from the database (including infant cereal milk
drink and instant porridge), as an estimate for average content in a food type (including infant formula
and chocolate) or an estimate based on brand name (including yoghurts). Based on the structure of the
database, the content of milk powder could not be estimated for some specific products (such as ice
cream, powder-based sauces, and certain prepared foods). From the dietary records, gluten intake
was also assessed as it was considered a confounding factor. Total intake of wheat, rye and barley
could be obtained from the database, and the amount of ingested gluten was calculated by multiplying
the analyzed content of protein in each of these grains with 0.8 for wheat, 0.65 for rye, and 0.5 for
barley [12].
Body weight was measured at every clinic visit at 3 months, 6 months, 9 months, 12 months,
18 months, and 24 months (Figure 2a). Scales were of different brands over the study period of which
Tanita (Tanita Corp, Tokyo, Japan) was most commonly applied. Tanita scale was the most common
and that scales were calibrated regularly. Energy intake for breastfed subjects was estimated using
the energy requirement based on the child’s age and weight at the time for the food record, then
subtracting the energy intake from other reported food (Figure 2b) [13].
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Figure 2. Body weight at clinic visit (a) and assessed daily mean intake of energy (kcal) (b), mean
daily intake of milk powder (gram per day) from 3-day food records in cases with celiac disease and
matched, healthy controls (1:3) (c). For breastfed subjects, energy intake was estimated using assessed
energy requirement and subtracting energy intake from other reported food. Controls were matched to
cases by gender, HLA genotype and birth year.
2.5. Statistical Analysis
Daily intake of milk powder in grams per day was assessed as the mean intake from the three-day
diet records. Intake data were available until 24 months of age, but age of tTGA seroconversion
for cases ranged from 10 to 120 months. Only available intakes reported prior to the case’s tTGA
seroconversion were included in analysis in order to compare between a case and matched control,
using conditional logistic regression. Daily intake was also analyzed in grams per kilogram body
weight (g/kg/day) in order to standardize intake between subjects. Intake reported at the visit prior
to the case’s tTGA seroconversion was as “last intake,” and the sum of all intakes assessed as “total
intake.” Intake at a given age (3 months, 6 months, 9 months, 12 months, 18 months, or 24 months)
was compared if it was available or appropriate for the case’s age of seroconversion. We first adjusted
for having a first-degree relative with celiac disease as a confounder. Milk powder intake was then
analyzed with and without adjustment for gluten intake in order to separate the effect on risk of
celiac disease between the two dietary exposures. Odds ratios were reported with 95% confidence
intervals (CI), along with two-sided p-value. Statistical significance was determined when p-value
<0.05. All statistical analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).
3. Results
Energy intake and body weight increased as expected with age for both cases and controls
(Figure 2a,b). The mean daily intake of milk powder increased in both cases and controls by 12 months
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of age and more significantly between 6 months and 9 months of age, respectively (Figure 2c).
At 6 months, the intake of milk powder was 15.9 g and 15.3 g per day for cases and controls respectively.
At 9 months it had increased to 28.1 grams and 25.4 grams per day for cases and controls and at
24 months it had decreased to 13.3 grams and 14.7 grams per day for cases and controls.
Neither energy intake nor body weight were associated with celiac disease. Intake of milk
powder in grams per day prior to seroconversion of tTGA positivity did not increase the risk of celiac
disease, either for last intake, nor total intake or for intake at any given age. This was also true for
the relative intake in grams per kg body weight (Table 2). In the unadjusted model, there was a
small increased risk for celiac disease for the milk powder intake at 9 months of age in grams per
day (OR = 1.01, 95%CI = 1.0–1.02; p = 0.037), as well as in grams per kilogram bodyweight per day
(OR = 1.1, 95%CI = 1.0–1.2; p = 0.044).
Table 2. Comparison of mean daily intake of milk powder (grams per day and grams per kilo
bodyweight) in cases with celiac disease and matched, healthy controls (1:3), and risk of celiac disease
analyzed with conditional logistic regression expressed as odds ratio (OR) after adjusting for having a
first-degree relative with celiac disease and for gluten intake at the given time point. Controls were
matched to cases by gender, HLA genotype and birth year.
Time point Number ofcases analyzed
Number of cases
missing intake
Milk powder intake (g/day) Milk powder intake (g/kg/day)
OR (CI 95%) p-value OR (CI 95%) p-value
Last intake 1 207 0 1.0 (0.99–1.01) 0.937 0.99 (0.87–1.13) 0.861
Total intake 2 207 0 1.0 (1.0–1.00) 0.662 1.0 (0.98–1.03) 0.763
Intake at
3 months 207 0 0.99 (0.97–1.01) 0.159 0.92 (0.83–1.02) 0.125
6 months 202 5 1.0 (0.99–1.02) 0.643 1.02 (0.91–1.13) 0.788
9 months 198 9 1.01 (1.0–1.02) 0.069 1.09 (0.99–1.19) 0.072
12 months 192 9 1.01 (1.0–1.02) 0.181 1.08 (0.96–1.21) 0.184
18 months 146 21 1.0 (0.98–1.02) 0.983 1.01 (0.84–1.21) 0.923
24 months 103 19 0.99 (0.97–1.01) 0.202 0.88 (0.69–1.12) 0.301
1 Last reported intake at the visit prior to seroconversion of tTGA; 2 Sum of all reported intakes prior to
seroconversion of tTGA
Having a first-degree relative with celiac disease (OR = 2.53, 95%CI 1.37, 4.67, p = 0.003) and
reported gluten intake when assessed in grams per day (OR = 1.09, 95%CI 1.03–1.16; p = 0.004) as well
as in grams per kilograms per day (OR = 2.73, 95%CI 1.36–5.49; p = 0.005) were associated with celiac
disease. When these confounders were included the adjusted model, the association between milk
powder intake and celiac disease no longer remained significant.
4. Discussion
The present study showed that intake of milk powder does not increase the risk of celiac disease
in genetically susceptible Swedish children. The peak intake of milk powder was observed at the age
of 9 months after which it started to decrease, and may reflect a dietary intake pattern of formula,
commercial porridge and milk cereal drink. The intake of milk powder observed was equivalent to the
amount of commercial porridge and cereal milk drink consumed by Swedish infants as reported in a
previous study [6].
The strength of the dietary assessment methods used in this study is that they allow for estimations
of individual intake of foods. Repeated food records measure changes in dietary habits of infants and
growing young children over time and is a suitable method when studying dietary intake and risk
of disease [14]. Another advantage with the dietary data collected for this study is minimization of
recall bias, which has been a limitation in previous studies using retrospective dietary assessment
methods [15,16]. A prospective study design has the advantage of unawareness of the tTGA status at
the time of the food data collection, which otherwise may influence parents to change their child’s diet.
Analysis of relative dietary intake we also made, as recommended in nutrition research and
disease [17]. The energy requirement of a child depends on age, weight, and growth [13]. A child
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larger in size may consume bigger portions than their smaller counterpart, resulting in a higher nutrient
intake, but not necessarily higher intake in relation to body weight. We adjusted for the confounders
of having a family member with celiac disease and for the gluten intake, respectively. The adjustments
had a significant impact on the results, since we found an association with increased risk for celiac
disease and intake of milk powder reported at the 9-month visit. We have previously published a
study on the association between amount of gluten intake and celiac disease performed on the same
cohort, which showed that the last intake of every gram gluten per day before seroconversion to tTGA
positivity increased the risk of celiac disease by 28% [3].
The limitations of this study includes that milk powder intake was only studied in the first 2 years
of life, whereas the majority of the celiac cases were diagnosed several years later. As 15.6% of the
subjects also had missing food record data at 24 months, data collected at earlier timepoints was
applied for the analyses, which may affect the reliability of the results. Additionally, we did not have
access to complete information on content of milk powder for all food items; therefore, estimates had to
be used. Although the excluded foods were considered less commonly used in the selected age groups,
estimations on possible amounts of missing data were not performed. In this study, we analyzed two
dietary exposures, and some common Swedish infant products contain both. Although the statistical
analyses adjusted for the gluten intake, the study could be criticized for not quantifying the amount of
gluten from products that also contained milk powder.
In conclusion, this nested case-control study on intake of milk powder during the first 2 years of
life in genetically susceptible children showed that consumption of milk powder is not associated with
celiac disease for Swedish children.
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